An accredited Developing
Stage business incubator
uk inspire Send this page | Bookmark | Print |

Business incubator for biotech and medtech startups


Diurnal launch as a virul enterprise

Diurnal launch as a virul enterprise



Launched as a virtual enterprise to address the lack of lifelong treatments for diseases caused by hormone imbalances, Diurnal is now set to access a worldwide market worth over £200 million a year.


Diurnal will soon enable patients with conditions such as congenital adrenal hyperplasia, which can lead to excessive facial hair, menstrual problems, kidney failure and even death, to be effectively treated from birth through to old age for the first time.


With the help of Welsh Government funding, Diurnal was able to restart development at the Cardiff Medicentre and make the product  a reality.  Its new base provided  the company access to IP Fusion, Finance Wales and Welsh Government Access Wales funding , enabling its two staff to lead clinical trials of prototype drug formulations with partners including, Merthyr Tydfil's Simbec Research. It also provided knowledge sharing links with University Hospital of Wales


The Welsh Government's Research, Development and Innovation funding programme enabled Diurnal to engage with European development partners that will give them access to worldwide markets.  These partners will now conclude patient trials before bringing initial paediatric treatments to market in 2015, while diurnal retains the licence for all therapies and plans to launch adult products by 2017


Diurnal CEO, Martin Whitaker, said "Producing any new therapy involves extensive R&D that does not lend itself to attracting traditional, private finding methods, but though the Welsh Government funding Diurnal found its feet physically and financially through support it simply would not have had means to access otherwise"


If you would like to find out more about funding and support from the Welsh Government:






Tel: 03000 6 03000

Published on Wed, 23rd Oct 2013

how to apply

Follow us

  • RSS Feed